Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedReid Merryman, MD has been added to the investigators list (noted on 2026-05-18 and 2026-05-04) and Philippe Armand, MD, PhD has been removed (noted on 2026-02-12, 2026-01-26, and 2023-07).SummaryDifference0.4%

- Check19 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, signaling a minor build/version update. This change represents an update to the page's revision history without altering visible content or user interactions.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThis change updates the page’s system/release revision label from v3.5.2 to v3.5.3, without altering the study record content.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No substantive changes to content or features.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision updated to v3.5.0; previous revision v3.4.3 has been removed.SummaryDifference0.1%

- Check91 days agoChange DetectedThe page shows a revision from v3.4.2 to v3.4.3. This appears to be a minor update with no changes to study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.